The company is currently developing a range of mRNA cancer therapeutics, including cancer and immunomodulatory cancer vaccines. Credit: KomootP / Shutterstock.
Everest Medicines has dosed the first subject with EVM16, the company’s personalised messenger ribonucleic acid (mRNA) cancer vaccine, in the first-in-human (FIH) trial, EVM16CX01.
The dosing procedures took place at Peking University Cancer Hospital in China.
This investigator-initiated trial aims to evaluate the vaccine’s immunogenicity, safety, preliminary efficacy, and tolerability as both a single agent and in conjunction with a programmed cell death protein 1 (PD-1) antibody in individuals with advanced or recurrent solid tumours.
It is co-conducted at the Fudan University Shanghai Cancer Center and Peking University Cancer Hospital, stated the company.
The trial’s primary objective is to assess the vaccine’s tolerability and safety as a single agent and in combination with PD-1.
In addition, the trial aims to determine the recommended Phase II dose of the vaccine. Secondary objectives include assessing the immunogenicity and initial efficacy of the vaccine with a PD-1 antibody.
Everest Medicines CEO Rogers Yongqing Luo said: “The first patient dosing marks a significant milestone in its clinical development of EVM16, indicating our proprietary tumor neoantigen AI-based algorithm system and mRNA technology platform have advanced to human trials.
“As a cancer vaccine candidate developed using our proprietary mRNA platform, we look forward to demonstrating EVM16’s therapeutic potential in upcoming clinical trials, with the goal of offering innovative treatment options to cancer patients worldwide and expanding choices for those facing life-threatening diseases.”
EVM16 is tailored to ‘encode’ several tumour neoantigens.
The company plans to file an investigational new drug application (IND) for its tumour-associated antigen (TAA) vaccines in both the US and China this year.
It is currently developing a suite of mRNA cancer therapeutics, which include personalised cancer vaccines (PCVs) and immunomodulatory cancer vaccines, as well as TAA vaccines.
mRNA vaccine coverage on Pharmaceutical Technology (Or Clinical Trials Arena) is supported by Trilink. Editorial content is independently produced and follows thehighest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Email newsletter icon
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.